* Skye Bioscience Inc SKYE.OQ SKYE.O is expected
to report
resultson May 10 for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Skye Bioscience Inc is
for a
loss of 16 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Skye
Bioscience
Inc is $22.50, above its last closing price of $12.07.
This summary was machine generated May 10 at 20:34 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)